GET DAILY SIGNALSABVC BioPharma (ABVC): What Investors Should Watch in the Upcoming Q3 2026 Earnings
Key Takeaways
- ABVC BioPharma, Inc. (Nasdaq: ABVC) is expected to report its third-quarter 2026 results in mid-November 2026, covering the three months ended September 30, 2026.
- Analyst consensus calls for a loss of $0.40 per share on revenue of approximately $0.11 million for the period.
- The year-ago quarter (Q3 2025) produced a loss of $0.05 per share on revenue of $0.80 million, implying a sharp expected decline in revenue.
- ABVC posted a surprise beat last quarter, reporting a loss of $0.03 per share versus a $0.40 loss consensus estimate.
- Investors will focus on the company's cash runway, operating expenses, and pipeline progress rather than top-line growth, given its clinical-stage status.
Why This Earnings Report Matters
ABVC BioPharma is a clinical-stage biopharmaceutical company developing plant-derived drugs and medical devices. Because it generates little to no product revenue, its quarterly earnings are less about sales and more about cost control, cash preservation, and clinical progress. The upcoming report matters because it will show whether the company can extend its cash runway and manage rising operating expenses, which climbed sharply earlier in the year due to stock-based compensation. With a going-concern warning already disclosed and a Nasdaq compliance history to manage, each quarterly update carries outsized weight for investors weighing the company's path toward potential commercialization and further financing.
What Analysts Are Expecting
For the third quarter of 2026, analyst consensus estimates point to a loss of $0.40 per share on revenue of roughly $0.11 million, according to data compiled by MarketBeat. That revenue figure would represent a decline of about 86% from the $0.80 million reported in the same quarter a year earlier, when the company posted a loss of $0.05 per share.
The wide gap between expectations and recent results reflects how difficult ABVC's quarterly performance is to forecast. In its most recent quarter (Q2 2026), the company reported a loss of $0.03 per share, significantly better than the $0.40 loss analysts had projected. Because ABVC is a micro-cap with limited analyst coverage, consensus figures should be viewed cautiously, and investors will likely watch operating expenses, net loss, and the company's cash and cash equivalents more closely than headline revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Heading into the Q3 2026 report, sentiment around ABVC remains cautious. The stock trades at a low per-share price with limited liquidity, and investors have been balancing the company's surprise earnings beat last quarter against its persistent losses, declining cash position, and going-concern disclosure. Micro-cap biotech names like ABVC often experience outsized price swings around earnings because any signal about financing, clinical setbacks, or Nasdaq compliance can dominate the narrative. Key risk factors include the company's thin cash balance, the need for additional capital, and uncertainty surrounding its clinical pipeline, which includes a Phase II program for a retinal device that was previously placed on hold due to safety concerns.
Forward Outlook and Key Factors to Monitor
After the Q3 2026 report, investors should focus first on the company's cash position and any commentary about financing. ABVC entered 2026 with a modest cash balance that has continued to decline, and management has already expressed substantial doubt about its ability to continue as a going concern. How the company plans to fund operations will be a central theme of the earnings call and forward guidance.
Pipeline progress will also be closely watched. The company's lead programs include a treatment candidate for attention-deficit/hyperactivity disorder (ADHD) and a retinal device for vitreous hemorrhage and retinal detachment. Any update on trial timelines, regulatory interactions with the U.S. Food and Drug Administration (FDA), or the previously halted retinal study could move sentiment meaningfully.
Finally, investors should monitor operating expense trends. A sharp rise in stock-based compensation drove much of the increase in expenses earlier in the year, and any sign that costs are stabilizing—or continuing to climb—will help frame the company's runway. Nasdaq listing compliance, given prior notices tied to stockholders' equity and bid price requirements, remains another factor worth tracking in the quarters ahead.
Using AI Tools for Deeper Analysis
One tool I’ve found particularly useful for this kind of analysis is Tickeron’s AI Screener. It helps me filter biotech names by technical patterns, fundamentals, and AI signals, making it easier to spot comparable setups and understand how ABVC fits into the broader sector without relying solely on limited analyst coverage.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABVC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 15, 2026
ABVC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 41 cases where ABVC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ABVC as a result. In 72 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ABVC just turned positive on October 22, 2026. Looking at past instances where ABVC's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
ABVC moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABVC crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.
Following a +11.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABVC advanced for three days, in 197 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABVC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ABVC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.591) is normal, around the industry mean (3.154). P/E Ratio (-3.448) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (27.397) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. ABVC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABVC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement